We recently compiled a list of the 10 High Growth Pharma Stocks That Are Profitable in 2025. Johnson & Johnson is placed second among them. Johnson & Johnson (NYSE:JNJ), a global leader in ...
9monon MSN
Johnson & johnson outlines $92B 2025 sales guidance amid innovative medicine and medtech growth
Q1 2025 Management View CEO Joaquin Duato highlighted strong operational sales growth of 4.2% with contributions from both Innovative Medicine and MedTech segments. He emphasized the company's ...
Johnson & Johnson MedTech, with support from the Johnson & Johnson Foundation, says it has donated $100 million of medtech ...
Q4 2025 Management View Joaquin Duato, CEO & Chairman, opened by emphasizing, "We said 2025 would be a catapult year for Johnson & Johnson, and that's exactly what it was. It was a year that launched ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results